Literature DB >> 12786754

Analysis of splice-site mutations of the alpha-galactosidase A gene in Fabry disease.

L-W Lai1, O Whitehair, M-J Wu, M O'Meara, Y-H H Lien.   

Abstract

Fabry disease is an X-linked disease caused by a defective lysosomal enzyme, alpha-galactosidase A, and characterized by skin lesions and multiorgan involvement, including kidney, heart, and the central nervous system. Currently more than 200 genotypes have been identified, including several aberrant splicing. However, most of the mutation analyses were performed using genomic sequencing only, and therefore some of the splicing mutations were misclassified as missense mutations. In order to predict the splicing event caused by each mutation, we conducted a literature search for all published mutations located near the splice sites, including exonic point mutations, and performed a splice-site score (SSS) analysis. The literature search identified 13 donor-site mutations, including four exonic mutations (S65T, D183S, K213N, and M267I), located at the end of exons 1, 3, 4, and 5, respectively, six acceptor-site mutations, and one new exon creation. All mutated splice sites, except for the one associated with the new exon creation, had a lower SSS than their respective natural sites. Cryptic or newly created sites were identified with SSS from 0.09 to 1.0. The predictions, based on SSS analysis, are in agreement with all six mutations with known cDNA sequence from the literature, including five mutations with exon skipping and one mutation with creation of a new acceptor site. For the S65T genotype, we performed reverse transcription-polymerase chain reaction (RT-PCR) analysis using RNA isolated from the whole-blood sample. We verified that a weak cryptic site (SSS = 0.09) 14 nucleotides downstream was activated and resulted in an insertion of 14 bp and a frameshift stop at codon 106. This change is more consistent with the clinical presentation of the patient, the classical Fabry disease, than the amino acid substitution (S65T), which does not affect the enzyme function. In conclusion, the SSS analysis is very useful for predicting splicing events and genotype/phenotype correlation in Fabry disease. As different mechanisms may be involved in pre-mRNA splicing, it is important to obtain cDNA sequencing for molecular diagnosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786754     DOI: 10.1034/j.1399-0004.2003.00077.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group.

Authors:  Andreas Gal; Derralynn A Hughes; Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2011-01-13       Impact factor: 4.982

2.  IL-7 receptor deficient SCID with a unique intronic mutation and post-transplant autoimmunity due to chronic GVHD.

Authors:  Manish J Butte; Charles Haines; Francisco A Bonilla; Jennifer Puck
Journal:  Clin Immunol       Date:  2007-09-12       Impact factor: 3.969

3.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

4.  A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Authors:  Xiaoyang Wu; Evan Katz; Maria Cecilia Della Valle; Kirsten Mascioli; John J Flanagan; Jeffrey P Castelli; Raphael Schiffmann; Pol Boudes; David J Lockhart; Kenneth J Valenzano; Elfrida R Benjamin
Journal:  Hum Mutat       Date:  2011-07-12       Impact factor: 4.878

Review 5.  Genetic architecture of common non-Alzheimer's disease dementias.

Authors:  Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

6.  Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene.

Authors:  Javier Gervas-Arruga; Jorge J Cebolla; Pilar Irun; Javier Perez-Lopez; Luis Plaza; Jose C Roche; Jose L Capablo; Jose C Rodriguez-Rey; Miguel Pocovi; Pilar Giraldo
Journal:  BMC Genet       Date:  2015-09-03       Impact factor: 2.797

7.  Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.

Authors:  Wen-Hsin Chang; Dau-Ming Niu; Chi-Yu Lu; Shyr-Yi Lin; Ta-Chih Liu; Jan-Gowth Chang
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.